Literature DB >> 30340932

PDA-TOLERATE Trial: An Exploratory Randomized Controlled Trial of Treatment of Moderate-to-Large Patent Ductus Arteriosus at 1 Week of Age.

Ronald I Clyman1, Melissa Liebowitz2, Joseph Kaempf3, Omer Erdeve4, Ali Bulbul5, Stellan Håkansson6, Johanna Lindqvist6, Aijaz Farooqi6, Anup Katheria7, Jason Sauberan7, Jaideep Singh8, Kelly Nelson8, Andrea Wickremasinghe9, Lawrence Dong9, Denise C Hassinger10, Susan W Aucott11, Madoka Hayashi11, Anne Marie Heuchan12, William A Carey13, Matthew Derrick14, Erika Fernandez15, Meera Sankar16, Tina Leone17, Jorge Perez18, Arturo Serize18.   

Abstract

OBJECTIVE: To compare early routine pharmacologic treatment of moderate-to-large patent ductus arteriosus (PDA) at the end of week 1 with a conservative approach that requires prespecified respiratory and hemodynamic criteria before treatment can be given. STUDY
DESIGN: A total of 202 neonates of <28 weeks of gestation age (mean, 25.8 ± 1.1 weeks) with moderate-to-large PDA shunts were enrolled between age 6 and 14 days (mean, 8.1 ± 2.2 days) into an exploratory randomized controlled trial.
RESULTS: At enrollment, 49% of the patients were intubated and 48% required nasal ventilation or continuous positive airway pressure. There were no differences between the groups in either our primary outcome of ligation or presence of a PDA at discharge (early routine treatment [ERT], 32%; conservative treatment [CT], 39%) or any of our prespecified secondary outcomes of necrotizing enterocolitis (ERT, 16%; CT, 19%), bronchopulmonary dysplasia (BPD) (ERT, 49%; CT, 53%), BPD/death (ERT, 58%; CT, 57%), death (ERT,19%; CT, 10%), and weekly need for respiratory support. Fewer infants in the ERT group met the rescue criteria (ERT, 31%; CT, 62%). In secondary exploratory analyses, infants receiving ERT had significantly less need for inotropic support (ERT, 13%; CT, 25%). However, among infants who were ≥26 weeks gestational age, those receiving ERT took significantly longer to achieve enteral feeding of 120 mL/kg/day (median: ERT, 14 days [range, 4.5-19 days]; CT, 6 days [range, 3-14 days]), and had significantly higher incidences of late-onset non-coagulase-negative Staphylococcus bacteremia (ERT, 24%; CT,6%) and death (ERT, 16%; CT, 2%).
CONCLUSIONS: In preterm infants age <28 weeks with moderate-to-large PDAs who were receiving respiratory support after the first week, ERT did not reduce PDA ligations or the presence of a PDA at discharge and did not improve any of the prespecified secondary outcomes, but delayed full feeding and was associated with higher rates of late-onset sepsis and death in infants born at ≥26 weeks of gestation. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01958320.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  bronchopulmonary dysplasia; necrotizing enterocolitis; newborn; premature birth; retinopathy of prematurity

Mesh:

Substances:

Year:  2018        PMID: 30340932      PMCID: PMC6502709          DOI: 10.1016/j.jpeds.2018.09.012

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  32 in total

1.  Mechanics of breathing after surgical ligation of patent ductus arteriosus in newborns with respiratory distress syndrome.

Authors:  Marta Szymankiewicz; Joan E Hodgman; Bijan Siassi; Janusz Gadzinowski
Journal:  Biol Neonate       Date:  2003-11-19

2.  Severity of the ductal shunt: a comparison of different markers.

Authors:  M El Hajjar; G Vaksmann; T Rakza; G Kongolo; L Storme
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-09       Impact factor: 5.747

3.  Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less.

Authors:  Josh Koch; Gaynelle Hensley; Lonnie Roy; Shannon Brown; Claudio Ramaciotti; Charles R Rosenfeld
Journal:  Pediatrics       Date:  2006-04       Impact factor: 7.124

4.  Early hemodynamic consequences of patent ductus arteriosus in preterm infants with intrauterine growth restriction.

Authors:  T Rakza; E Magnenant; S Klosowski; P Tourneux; A Bachiri; L Storme
Journal:  J Pediatr       Date:  2007-08-24       Impact factor: 4.406

5.  The ductus arteriosus rarely requires treatment in infants > 1000 grams.

Authors:  Sheri L Nemerofsky; Elvira Parravicini; David Bateman; Charles Kleinman; Richard A Polin; John M Lorenz
Journal:  Am J Perinatol       Date:  2008-10-10       Impact factor: 1.862

Review 6.  Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis?

Authors:  W E Benitz
Journal:  J Perinatol       Date:  2010-02-25       Impact factor: 2.521

7.  Feeding practices and patent ductus arteriosus ligation preferences-are they related?

Authors:  Nami Jhaveri; Roger F Soll; Ronald I Clyman
Journal:  Am J Perinatol       Date:  2010-03-11       Impact factor: 1.862

Review 8.  Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.

Authors:  Arne Ohlsson; Sachin S Shah
Journal:  Cochrane Database Syst Rev       Date:  2011-07-06

9.  The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study.

Authors:  William V Good; Robert J Hardy; Velma Dobson; Earl A Palmer; Dale L Phelps; Michelle Quintos; Betty Tung
Journal:  Pediatrics       Date:  2005-07       Impact factor: 7.124

10.  Enteral feeding during indomethacin and ibuprofen treatment of a patent ductus arteriosus.

Authors:  Ronald Clyman; Andrea Wickremasinghe; Nami Jhaveri; Denise C Hassinger; Joshua T Attridge; Ulana Sanocka; Richard Polin; Maria Gillam-Krakauer; Jeff Reese; Mark Mammel; Robert Couser; Neil Mulrooney; Toby D Yanowitz; Matthew Derrick; Priya Jegatheesan; Michele Walsh; Alan Fujii; Nicolas Porta; William A Carey; Jonathan R Swanson
Journal:  J Pediatr       Date:  2013-03-06       Impact factor: 4.406

View more
  40 in total

1.  Continuing interventions in a quality improvement bundle to reduce bronchopulmonary dysplasia.

Authors:  Yan-Ping Xu; Li-Ping Shi; Li-Zhong Du
Journal:  World J Pediatr       Date:  2022-02-18       Impact factor: 2.764

2.  Natural evolution of the patent ductus arteriosus in the extremely premature newborn and respiratory outcomes.

Authors:  Gabriela de Carvalho Nunes; Punnanee Wutthigate; Jessica Simoneau; Marc Beltempo; Guilherme Mendes Sant'Anna; Gabriel Altit
Journal:  J Perinatol       Date:  2021-11-23       Impact factor: 2.521

Review 3.  Patent Ductus Arteriosus of the Preterm Infant.

Authors:  Shannon E G Hamrick; Hannes Sallmon; Allison T Rose; Diego Porras; Elaine L Shelton; Jeff Reese; Georg Hansmann
Journal:  Pediatrics       Date:  2020-11       Impact factor: 7.124

Review 4.  Does crossover treatment of control subjects invalidate results of randomized trials of patent ductus arteriosus treatment?

Authors:  Meera N Sankar; William E Benitz
Journal:  J Perinatol       Date:  2020-10-06       Impact factor: 2.521

5.  Prolonged Tracheal Intubation and the Association Between Patent Ductus Arteriosus and Bronchopulmonary Dysplasia: A Secondary Analysis of the PDA-TOLERATE trial.

Authors:  Ronald I Clyman; Joseph Kaempf; Melissa Liebowitz; Omer Erdeve; Ali Bulbul; Stellan Håkansson; Johanna Lindqvist; Aijaz Farooqi; Anup Katheria; Jason Sauberan; Jaideep Singh; Kelly Nelson; Andrea Wickremasinghe; Lawrence Dong; Denise C Hassinger; Susan W Aucott; Madoka Hayashi; Anne Marie Heuchan; William A Carey; Matthew Derrick; Erika Fernandez; Meera Sankar; Tina Leone; Jorge Perez; Arturo Serize
Journal:  J Pediatr       Date:  2020-10-28       Impact factor: 4.406

6.  Indomethacin for symptomatic patent ductus arteriosus in preterm infants.

Authors:  Peter Evans; Deirdre O'Reilly; Jonathan N Flyer; Roger Soll; Souvik Mitra
Journal:  Cochrane Database Syst Rev       Date:  2021-01-15

7.  Relative effectiveness and safety of pharmacotherapeutic agents for patent ductus arteriosus (PDA) in preterm infants: a protocol for a multicentre comparative effectiveness study (CANRxPDA).

Authors:  Souvik Mitra; Amish Jain; Joseph Y Ting; Nadya Ben Fadel; Christine Drolet; Ayman Abou Mehrem; Amuchou Soraisham; Bonny Jasani; Deepak Louis; Anie Lapointe; Jon Dorling; Faiza Khurshid; Abbas Hyderi; Kumar Kumaran; Jaya Bodani; Dany Weisz; Ruben Alvaro; Mohammed Adie; Miroslav Stavel; Alyssa Morin; Soume Bhattacharya; Jaideep Kanungo; Rody Canning; Xiang Y Ye; Tara Hatfield; Courtney E Gardner; Prakesh Shah
Journal:  BMJ Open       Date:  2021-05-05       Impact factor: 2.692

8.  Surgical management of patent ductus arteriosus in pre-term infants - a british paediatric surveillance study.

Authors:  A Warnock; L Szatkowski; A Lakshmanan; L Lee; W Kelsall
Journal:  BMC Pediatr       Date:  2021-06-09       Impact factor: 2.125

9.  Eligibility Criteria and Representativeness of Randomized Clinical Trials That Include Infants Born Extremely Premature: A Systematic Review.

Authors:  Leeann R Pavlek; Brian K Rivera; Charles V Smith; Joanie Randle; Cory Hanlon; Kristi Small; Edward F Bell; Matthew A Rysavy; Sara Conroy; Carl H Backes
Journal:  J Pediatr       Date:  2021-04-21       Impact factor: 6.314

10.  Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants.

Authors:  Souvik Mitra; Alexandra Scrivens; Adelaide M von Kursell; Tim Disher
Journal:  Cochrane Database Syst Rev       Date:  2020-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.